Press release
TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026
• Research Methodology
• Global & Regional Market Analysis
• Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion
• Market and Drug Sales Insight 2020 Till 2026
• Approved Drug In Market: 1 Drugs
• Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026
• Future Market Assessment By Indication Till 2026
• Ongoing Clinical Trials Assessment by Status, Phase & Region
• Key Market Dynamics
• Competitor Landscape
Download Report:
https://www.kuickresearch.com/report-global-trop-2-antibody-adc-drug-conjugate-market-sales-trodelvy-sacituzumab-govitecan
Triple negative breast cancer accounts for approximately 15%-20% of the cases and is mainly characterized by lack of expression of estrogen receptor (ER), progestrone receptor (PR) and human epidermal growth factor receptor-2 (Her-2). Despite the discovery of several targeted therapies in wide range of cancers, only limited targeted drugs have been approved for the management of TNBC patients owing to its high aggressive nature. Several researchers have revealed potential molecular targets and different drug types which have make their way into the market. Recently, scientists have identified trophoblast cell-surface antigen 2 as a potential therapeutic target for triple negative breast cancer.
Extensive research activities in this field have led to the development of several TROP2 directed drugs. Trodelvy (Sacituzumab govitecan/IMMU-132) is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate developed by Immunomedics which has been approved for commercial use. It targets the Trop-2 antigen through humanised monoclonal antibody, expressed on various tumour cells and delivers SN-38, a topoisomerase I inhibitor, to the tumours directly, causing cell death.The clinical trials with the drug demonstrated high efficacy and considerable increase in overall survival and progression free survival rates of triple negative breast cancer patients.
The approval of drug Trodelvy in 2020 is thought to revolutionize the paradigm treatment of metastatic triple negative breast cancer patients. It is expected that in short span of time, the drug will constitute a major share in the breast cancer therapeutics owing to its specific and selective nature towards cancer cell. It is analyzed that the market will witness high compound annual growth rates to reach a value of US$ 4 Billion by 2026. Apart from this, the favorable reimbursement policies by government including Trodelvy Access Service will help in lowering the overall cost of the therapy, further fueling the growth of market for next few years.
Apart from its expression in TNBC, the receptor is also over-expressed in several other cancers including non-small cell lung cancer, colon cancer, prostate, gastric, and urothelial cancers. Therefore, several ongoing clinical trials are evaluating the role of drug in other cancers including hormone receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic non-small cell lung cancer, endometrial carcinoma, urothelial cancer, glioblastoma and hepatocellular carcinoma. Additional clinical trials are also evaluating the combination of drug with talazoparib, nivolumab, carboplatin, and other cancer therapeutics to enhance the efficacy of the drug. Te extended approval of the drug in other therapeutic conditions will also propel the growth of market.
The increasing sales of Trodelvy has also surged further research and development in this sector. To date, a cocktail of Trop 2 targeted therapies are currently present in clinical trials which are expected to enter the market duing forecast period. The pipeline of Trop 2 targeting drugs is highly crowded and consists of several candidates including DS-1062a, RN927C, BAT8003, SKB264, and JS108. Apart from this, pharmaceutical giants have entered into collobartion or partnerships to drive the researcg and development in this sector. For instance, Sorrento partnered with Escugen Biotechnology to evaluate recombinant humanized anti-Trop2 Mab-SN38 Conjugate.
The coming years will witness high growth rate in global Trop2 targeted therapies owing to increase in geriatric population and subsequent increase in prevalence of cancer. The growing demand of targeted therapies and the encouraging response of approved drugs will also drive the market in coming years. Moreover, the increasing number of product launches and the rising adoption rates of targeted treatments due to its higher achievement in terms of efficient treatment leading to improved patient outcomes are expected to contribute to the growth of market at higher compound annual growth rates during the forecast period.
Contact:
Neeraj Chawla
Research head
Kuick Research
neeraj@kuickresearch.com
+91-9810410366
India
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026 here
News-ID: 2468174 • Views: …
More Releases from Kuick Resarch
Targeted Alpha Therapy Market
Global Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028 Report Highlights:
• Global Targeted Alpha Therapy Market Insight By Region
• Approved Targeted Alpha Therapy Dosage & Pricing Insight
• Number Of Targeted Alpha Therapy In Clinical Trials: > 20 Drugs
• Targeted Alpha Therapy Clinical Trials Insight By Company, Country, Indication & Phase
• Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication
• Targeted Alpha Therapy Proprietary Technology Platform Insights By…
Global Cancer Antibody Drug Conjugates Market
Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 Report Finding & Inclusions:
• Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
• Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
• Approved Cancer Antibody Drug Conjugates: 16 Drugs
• Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis
• Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
• Cancer Antibody Drug Conjugates Clinical…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
More Releases for TROP2
Trop2 Antibodies for Personalized Cancer Treatment
Personalized cancer treatment has become a central focus in oncology, aiming to tailor therapies to the unique genetic and molecular profiles of individual patients. Trop2 antibodies, which target the Trop2 protein overexpressed in various cancers, have emerged as a promising tool in this personalized approach. By targeting a specific biomarker present in a patient's tumor, Trop2 antibodies offer a more precise and effective treatment option, minimizing the side effects associated…
New Developments in Trop2 Antibody Research
Research into Trop2 antibodies has gained significant momentum in recent years, driven by the promising results seen in clinical trials and the growing understanding of Trop2's role in cancer biology. Trop2, a transmembrane glycoprotein overexpressed in many epithelial cancers, has become a prime target for therapeutic intervention. The ongoing research into Trop2 antibodies is not only expanding our knowledge of how these therapies work but also leading to the development…
How Trop2 Antibodies Are Changing Cancer Treatment
The treatment landscape for cancer has undergone significant changes with the advent of targeted therapies, and Trop2 antibodies are at the forefront of this revolution. Trop2, a cell surface glycoprotein, is overexpressed in a variety of epithelial cancers, including breast, colorectal, and lung cancers. Its overexpression is often associated with poor prognosis, making it an ideal target for therapeutic intervention. Trop2 antibodies, particularly in the form of antibody-drug conjugates (ADCs),…
The Future of Cancer Therapy with Trop2 Antibodies
The landscape of cancer therapy is rapidly evolving, and Trop2 antibodies are poised to play a crucial role in its future. Trop2, a transmembrane glycoprotein overexpressed in various epithelial cancers, has become a significant target for therapeutic intervention. The development and success of Trop2 antibodies, particularly in the form of antibody-drug conjugates (ADCs), signal a new era in cancer treatment that prioritizes precision, efficacy, and patient-centered care. As research continues…
The Potential of Trop2 Antibodies in Treating Tumors
Trop2, or trophoblast cell surface antigen 2, has emerged as a significant biomarker and therapeutic target in oncology due to its overexpression in a wide range of epithelial tumors. This overexpression is often correlated with aggressive tumor behavior, making Trop2 an attractive target for therapeutic intervention. Trop2 antibodies, designed to specifically target this protein, hold substantial potential in treating various tumors, particularly those that are resistant to traditional therapies.
Download Report:
https://www.kuickresearch.com/report-trop2-antibodies-market-clinical-trials
The…
Trop2 Antibodies in Cancer Therapy
Trop2, a transmembrane glycoprotein, has garnered significant attention in oncology due to its overexpression in various types of cancers, including breast, ovarian, lung, and colorectal cancers. The overexpression of Trop2 is often associated with aggressive tumor behavior and poor prognosis, making it an attractive target for cancer therapy. Trop2 antibodies have emerged as a promising tool in targeted cancer treatment, offering a more precise approach compared to traditional therapies.
Download Report:
https://www.kuickresearch.com/report-trop2-antibodies-market-clinical-trials
Trop2…
